Evidence map›Paper›PMID 42095120›Full record

ArticleLiver cancer2026

Low Tumor Burden Predicts Benefit from Transarterial Treatment in Hepatocellular Carcinoma with Extrahepatic Metastasis: A Nationwide Cohort Study.

Jaejun Lee, Hyun Yang, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jaejun LeeThe Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hyun YangThe Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Keungmo YangThe Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Ji Won HanThe Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Pil Soo SungThe Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Jeong Won JangThe Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Si Hyun BaeThe Catholic University Liver Research Center, Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: In patients with hepatocellular carcinoma (HCC) and extrahepatic metastasis (EHM), intrahepatic disease control may remain clinically relevant in selected cases. This study aimed to compare survival outcomes between transarterial treatment (TAT) and systemic therapy (ST) as initial treatment. Methods: Data from the Korean Central Cancer Registry (2008-2020) were analyzed. TAT included chemoembolization, radioembolization, and hepatic arterial infusion chemotherapy. Systemic therapy consisted predominantly of tyrosine kinase inhibitors (>98%). Overall survival (OS) was the primary endpoint. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) adjusted for confounding. Results: Among 19,753 treatment-naïve HCC patients, 2,517 had EHM. Of these, 663 received TAT and 595 received ST as initial therapy. In the overall cohort, TAT was associated with significantly longer OS than ST (median OS: 6.7 vs. 3.7 months, Conclusion: These findings suggest that TAT may be a viable initial treatment option for selected HCC patients with EHM, particularly those with lower tumor burden. Further comparative studies, especially with immunotherapy, are needed to define its optimal role in clinical practice.

Indexed as

Extrahepatic metastasisHepatocellular carcinomaOverall survivalSystemic therapyTransarterial treatment

Identifiers

PMID42095120
PMCPMC13143332

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.